微信小陈
微信小章| 产品名称： | anti-SC35 |
|---|---|
| 商品货号： | TS212676 |
| Organism： | Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma) |
| Cell Type： | hybridoma: B lymphocyte |
| Product Format： | frozen |
| Morphology： | lymphoblast |
| Culture Properties： | suspension, suspension |
| Biosafety Level： | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Applications： | The antibody reacts with a 35000 dalton protein present in nuclear extracts. It can be used to deplete nuclear extracts of splicing activity, to detect mammalian SC35 by Western blot, to precipitate purified spliceosomes and to study mRNA splicing in vitro. |
| Storage Conditions： | liquid nitrogen vapor phase |
| Derivation： | Animals were immunized with 60S spliceosomes purified by gel filtration. Spleen cells were fused with FOX-NY myeloma cells. It can be used to deplete nuclear extracts of splicing activity, to detect mammalian SC35 by Western blot, to precipitate purified spliceosomes and to study mRNA splicing in vitro. |
| Genes Expressed： | immunoglobulin; monoclonal antibody; against mammalian splicing factor (SC35) |
| Cellular Products： | immunoglobulin; monoclonal antibody; against mammalian splicing factor (SC35) |
| Comments： | Animals were immunized with 60S spliceosomes purified by gel filtration. Spleen cells were fused with FOX-NY myeloma cells. The antibody reacts with a 35000 dalton protein present in nuclear extracts. On Western blots, the antibody detects a doublet at about 35000 daltons. It can be used to deplete nuclear extracts of splicing activity, to detect mammalian SC35 by Western blot, to precipitate purified spliceosomes and to study mRNA splicing in vitro. |
| Complete Growth Medium： | RPMI 1640 medium with 2 mM L-glutamine adjusted to contain 1.5 g/L sodium bicarbonate, 4.5 g/L glucose, 10 mM HEPES, and 1.0 mM sodium pyruvate supplemented with 0.1 mM hypoxanthine, 400 nM aminopterin, 0.016 mM thymidine, and 0.05 mM 2-mercaptoethanol, 90%; fetal bovine serum, 10%
|
| Subculturing： | Cultures can be maintained by addition of fresh medium or replacement of medium. Alternatively cultures can be established by centrifugation with subsequent resuspension at 1 to 2 x 105 viable cells/mL. Maintain cell density between 105 and 106 viable cells/mL. Medium Renewal: Add fresh medium as cell density increases, about every 2 to 3 days. |
| Cryopreservation： | Complete growth medium described above supplemented with 5% (v/v) DMSO.xa0 Cell culture tested DMSO is available as ATCC Catalog No. 4-X. |
| Culture Conditions： | Temperature: 37°C
Atmosphere: Air, 95%; Carbon dioxide (CO2), 5% |
| Isotype： | IgG1 |
| Name of Depositor： | X Fu, T Maniatis |
| Deposited As： | mouse (B cell); mouse (myeloma) |
| References： | Fu XD, Maniatis T. Factor required for mammalian spliceosome assembly is localized to discrete regions in the nucleus. Nature 343: 437-441, 1990. PubMed: 2137203 Spector DL, et al. Associations between distinct pre-mRNA splicing components and the cell nucleus. EMBO J. 10: 3467-3581, 1991. PubMed: 1833187 Fu XD, Maniatis T. The 35-kDa mammalian splicing factor SC35 mediates specific interactions between U1 and U2 small nuclear ribonucleoprotein particles at the 3 splice site. Proc. Natl. Acad. Sci. USA 89: 1725-1729, 1992. PubMed: 1531875 Fu XD, Maniatis T. Isolation of a complementary DNA that encodes the mammalian splicing factor SC35. Science 256: 535-538, 1992. PubMed: 1373910 Hay, R. J., Caputo, J. L., and Macy, M. L., Eds. (1992), ATCC Quality Control Methods for Cell Lines. 2nd edition, Published by ATCC. Caputo, J. L., Biosafety procedures in cell culture. J. Tissue Culture Methods 11:223-227, 1988. Fleming, D.O., Richardson, J. H., Tulis, J.J. and Vesley, D., (1995) Laboratory Safety: Principles and Practice. Second edition, ASM press, Washington, DC. Biosafety in Microbiological and Biomedical Laboratories, 5th ed. HHS. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. Washington DC: U.S. Government Printing Office; 2007. The entire text is available online. |